The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we see a gene therapy succeed in helping patients with a rare liver disease maintain their blood sugar. We see an Ionis drug do better than already-approved competitors in a rare swelling disease, and we see some conflict-of-interest issues from doctors on X.
